AUTH/3782/6/23 - Complainant v AstraZeneca

Alleged misleading information on AstraZeneca’s Forxiga webpage

  • Received
    22 June 2023
  • Case number
  • Applicable Code year
  • Completed
    08 March 2024
  • No breach Clause(s)
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to the ‘Prescribing and Dosing’ webpage of the Forxiga (dapagliflozin) promotional website. The complainant alleged that the webpage was misleading with regard to information presented on Forxiga’s renal considerations.

The outcome under the 2021 Code was:

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards at all times

No Breach of Clause 6.1

Requirement that information must be accurate, up-to-date and not misleading

No Breach of Clause 6.2

Requirement that information/claims/comparisons must be capable of substantiation

This summary is not intended to be read in isolation.
For full details, please see the full case report below.